Meeting
2021 ASCO Annual Meeting
A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).
Authors
Hiroo Katsuya
Saga University, Saga, Japan
Hiroo Katsuya , Koichi Suyama , Kazuma Kobayashi , Naoki Izawa , Yoshikazu Uenosono , Qingjiang Hu , Tetsuya Kusumoto , Hajime Otsu , Hiroyuki Orita , Hirofumi Kawanaka , Kazunori Shibao , Satoshi Koga , Mototsugu Shimokawa , Akitaka Makiyama , Hiroshi Saeki , Eiji Oki , Hideo Baba , Masaki Mori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
UMIN000028309
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4043)
DOI
10.1200/JCO.2021.39.15_suppl.4043
Abstract #
4043
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT).
First Author: Kenro Hirata
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Geriatric-8 (G8) screening tool stratified the efficacy of S-1 plus ramucirumab in elderly patients with advanced/recurrent gastric cancer: A post-hoc analysis of the KSCC1701 trial.
First Author: Qingjiang Hu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study).
First Author: Yuhong Dai